Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Memphasys Ltd ( (AU:MEM) ).
Memphasys Limited has made significant strides in its operations during the June 2025 quarter, notably with the completion of the CE Mark submission for its Felix™ system, which is expected to open access to Europe’s IVF market. The company has also pivoted its commercial strategy to focus on direct sales in low-regulatory markets such as Japan, New Zealand, UAE, and Canada, achieving repeat sales in Japan. Additionally, Memphasys has advanced its RoXsta™ platform, which has shown potential in various applications, including fertility and sports medicine, and is preparing for large-scale studies. The company is also reviewing its manufacturing and supply chain processes to optimize costs and ensure regulatory compliance, positioning itself for efficient global scaling.
More about Memphasys Ltd
Memphasys Limited is a biotechnology company focused on developing and commercializing innovative products for assisted reproduction. The company is engaged in creating solutions like the Felix™ Sperm Separation System and the RoXsta™ oxidative stress diagnostic platform, targeting markets such as human fertility, veterinary reproduction, and elite sports performance.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$9.92M
Learn more about MEM stock on TipRanks’ Stock Analysis page.